Comparison of clinical symptoms, gastric motility and fat intake in the early chronic pancreatitis patients with anti-acid therapy-resistant functional dyspepsia patients

PLoS One. 2018 Nov 7;13(11):e0205165. doi: 10.1371/journal.pone.0205165. eCollection 2018.

Abstract

Background: There was no available data concerning the clinical differentiation between the updated definition of early chronic pancreatitis (ECP) and anti-acid therapy-resistant functional dyspepsia (RFD).

Aims: We aimed to determine whether clinical symptoms, gastric motility, psychogenic factors and fat intake can help distinguish early chronic pancreatitis (ECP) from anti-acid therapy-resistant functional dyspepsia patients with pancreatic enzyme abnormalities (RFD-P) and anti-acid therapy-resistant functional dyspepsia (RFD) patients using endosonography.

Methods: We enrolled 102 consecutive patients presenting with typical symptoms of RFD patients (n = 52), ECP patients (n = 25) and RFD-P patients (n = 25). ECP patients were diagnosed based on the criteria recommended by the Japan Pancreatic Association. Gastric motility was evaluated by 13C-acetate breath tests. Severity of duodenal inflammation was examined.

Results: 24.5% of RFD patients were determined as ECP using endosonography. Abdominal pain score in Gastrointestinal Symptom Rating Scale (GSRS) in the patients with ECP was significantly lower compared to that in the patients with RFD-P. There were no significant differences in State-Trait Inventory (STAI)-state/-trait scores, Self-Rating Questionnaire for Depression (SRQ-D) scores and clinical symptoms for fat intake among three groups. The early phase of gastric emptying (AUC5; AUC15) in ECP and RFD-P patients were significantly disturbed compared to those in RFD patients.

Conclusions: Evaluation of severity of abdominal pain and measurement of the early phase of gastric emptying will be useful tools to distinguish ECP patients from RFD patients. Accurate diagnosis of ECP patients may contribute to the prevention from advancing of chronic pancreatitis.

MeSH terms

  • Adult
  • Anti-Ulcer Agents / therapeutic use
  • Dietary Fats* / administration & dosage
  • Disease Management
  • Drug Resistance
  • Dyspepsia / diagnosis
  • Dyspepsia / drug therapy
  • Dyspepsia / physiopathology*
  • Endosonography
  • Female
  • Gastric Emptying
  • Gastrointestinal Motility*
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Function Tests
  • Pancreatitis, Chronic / diagnosis*
  • Pancreatitis, Chronic / physiopathology*
  • Risk Factors
  • Symptom Assessment
  • Workflow

Substances

  • Anti-Ulcer Agents
  • Dietary Fats

Grants and funding

This study was supported by the Ministry of Education, Culture, and Science and from the Ministry of Health, Japan (16K09294) (SF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.